CervoMed Announces $10.5M Placement, Shares Drop 22% Pre-Market
CRVO•CervoMed Inc experienced a 22% pre-market drop after announcing a $10.5M private placement at $3.14 per unit and potential $21.7M warrants, backed by insiders and healthcare investors. The financing will extend cash runway into Q2 2027 and fund late-stage development of Neflamapimod for dementia with Lewy bodies.
1. Stock Decline Following Financing Announcement
CervoMed shares plummeted more than 22% in pre-market trading, approaching their lowest level in over a year and marking the largest single-day slump since March 2025.
2. Private Placement Terms
The company plans to sell approximately 3.36 million units at $3.14 per unit—a near 9% premium to the previous closing price—comprising common stock, pre-funded warrants, and Series B and C warrants.
3. Cash Runway Extension and Fund Use
The placement will generate $10.5M upfront, with potential to raise an additional $21.7M if all warrants are exercised, extending the cash runway into Q2 2027 and supporting a strategic partnership for late-stage development of Neflamapimod for dementia with Lewy bodies.
4. Insider and Institutional Backing
Institutional healthcare investors led the financing, with participation from board chair Joshua S. Boger, President and CEO John J. Alam–related trusts, and director Sylvie Grégoire, demonstrating strong insider support.
